Table 4.
Univariate and multivariate analysis in disease‐free survival and overall survival of stage I AC patients
| DFS | OS | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
| Variables | HR | 95% CI | P a | HR | 95% CI | P a | HR | 95% CI | P a | HR | 95% CI | P a |
| Sex | ||||||||||||
| Women | 1.0 | 1.0 | 1.0 | 1.0 | ||||||||
| Men | 3.32 | 1.77–6.21 | <0.0001 | 2.11 | 0.90–4.98 | 0.087 | 7.39 | 3.05–17.9 | <0.0001 | 5.69 | 1.78–18.2 | 0.003 |
| Age | ||||||||||||
| <70 | 1.0 | 1.0 | 1.0 | 1.0 | ||||||||
| ≥70 | 2.75 | 1.50–5.03 | 0.001 | 1.95 | 1.04–3.66 | 0.039 | 3.07 | 1.50–6.27 | 0.002 | 2.39 | 1.12–5.09 | 0.024 |
| Smoking history | ||||||||||||
| Never smoker | 1.0 | 1.0 | 1.0 | 1.0 | ||||||||
| Smoker | 3.4 | 1.84–6.29 | <0.0001 | 0.919 | 0.60–1.42 | 0.22 | 4.73 | 2.21–10.1 | <0.0001 | 1.14 | 0.69–1.91 | 0.089 |
| p53 Arg72Pro | ||||||||||||
| Arg/Arg + Arg/Pro | 1.0 | 1.0 | ||||||||||
| Pro/Pro | 0.82 | 0.37–1.83 | 0.62 | 0.80 | 0.31–2.07 | 0.65 | ||||||
| MDM2 c.309T>G | ||||||||||||
| T/G + G/G | 1.0 | 1.0 | 1.0 | 1.0 | ||||||||
| T/T | 1.71 | 0.92–3.15 | 0.09 | 1.45 | 0.76–2.76 | 0.254 | 2.20 | 1.10–4.36 | 0.025 | 2.23 | 1.07–4.65 | 0.033 |
| Performance status | ||||||||||||
| 0 | 1.0 | 1.0 | ||||||||||
| 1,2 | 0.94 | 0.29–3.05 | 0.92 | 1.34 | 0.41–4.43 | 0.63 | ||||||
| Differentiation | ||||||||||||
| Well | 1.0 | 1.0 | 1.0 | 1.0 | ||||||||
| Moderate and poorly | 3.94 | 2.08–7.48 | <0.0001 | 0.79 | 0.54–1.16 | 0.22 | 4.76 | 2.16–10.5 | <0.0001 | 0.79 | 0.49–3.31 | 0.34 |
| T factor | ||||||||||||
| T1 | 1.0 | 1.0 | 1.0 | |||||||||
| T2 | 2.93 | 1.64–5.23 | <0.0001 | 1.76 | 0.84–3.72 | 0.14 | 2.62 | 1.34–5.11 | 0.005 | 1.27 | 0.49–3.31 | 0.62 |
| Lymphovascular invasion | ||||||||||||
| Negative | 1.0 | 1.0 | 1.0 | |||||||||
| Positive | 4.36 | 2.43–7.82 | <0.0001 | 1.48 | 1.04–2.10 | 0.03 | 6.10 | 3.00–12.4 | <0.0001 | 2.50 | 1.03–6.11 | 0.044 |
| Pleural invasion | ||||||||||||
| Negative | 1.0 | 1.0 | 1.0 | 1.0 | ||||||||
| Positive | 2.49 | 1.35–4.60 | 0.004 | 1.19 | 0.542–2.61 | 0.66 | 3.00 | 1.51–5.96 | 0.002 | 1.13 | 0.44–2.90 | 0.80 |
| EGFR gene mutation | ||||||||||||
| Mutant | 1.0 | 1.0 | 1.0 | |||||||||
| Wild type | 2.02 | 1.08–3.78 | 0.027 | 2.94 | 1.34–6.48 | 0.007 | 1.46 | 0.60–3.56 | 0.41 | |||
| KRAS gene mutation | ||||||||||||
| Wild type | 1.0 | 1.0 | ||||||||||
| Mutant | 1.13 | 0.51–2.53 | 0.76 | 1.31 | 0.54–3.16 | 0.55 | ||||||
| p53 gene mutation | ||||||||||||
| Wild type | 1.0 | 1.0 | ||||||||||
| Mutant | 1.43 | 0.69–2.97 | 0.33 | 1.75 | 0.79–3.84 | 0.17 | ||||||
| Adjuvant chemotherapy | ||||||||||||
| Not received | 1.0 | 1.0 | ||||||||||
| Received | 1.56 | 0.79–3.07 | 0.2 | 1.25 | 0.54–2.89 | 0.6 | ||||||
HR and 95% CI are shown as the values of the latter compared to the former (HR = 1.0). P < 0.05 are shown in bold. DFS, disease‐free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.
a
P values were calculated by Cox regression analysis.